Growth & profitability
- Revenue has grown 275.3% per year over the past 5 years.
Financial health
- Operating income covered interest expense 9.5× in the latest year.
ATRA Financials Atara Biotherapeutics, Inc.
13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $121M | $33M | 0.0% | 29.7% | -$51M | — | $8M |
| 2024 | $129M | -$85M | 0.0% | -64.7% | -$69M | — | $25M |
| 2023 | $9M | -$276M | 0.0% | -3219.5% | -$194M | — | $26M |
| 2022 | — | -$228M | — | — | -$275M | — | $93M |
| 2021 | — | -$340M | — | — | -$231M | — | $106M |
| 2020 | — | -$307M | — | — | -$185M | — | $200M |
| 2019 | — | -$291M | — | — | -$241M | — | $74M |
| 2018 | — | -$231M | — | — | -$216M | — | $61M |
| 2017 | — | -$119M | — | — | -$108M | — | $79M |
| 2016 | — | -$79M | — | — | -$63M | — | $48M |
| 2015 | — | -$57M | — | — | — | — | $24M |
| 2014 | — | -$28M | — | — | — | — | $22M |
| 2013 | — | -$9M | — | — | — | — | $52M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $516000 | -$4M | 0.0% | -652.9% | — | — | $8M |
| Dec '25 | $2M | -$3M | 0.0% | -160.7% | -$6M | — | $8M |
| Sep '25 | $3M | -$4M | 0.0% | -103.5% | -$10M | — | $6M |
| Jun '25 | $18M | $2M | 0.0% | 18.2% | -$7M | — | $17M |
| Mar '25 | $98M | $38M | 0.0% | 39.5% | -$28M | — | $14M |
| Dec '24 | $33M | -$13M | 0.0% | -37.3% | -$25M | — | $25M |
| Sep '24 | $40M | -$22M | 0.0% | -54.1% | -$4M | — | $46M |
| Jun '24 | $29M | -$19M | 0.0% | -63.7% | -$11M | — | $31M |
| Mar '24 | $27M | -$32M | 0.0% | -114.2% | -$30M | — | $35M |
| Dec '23 | — | -$60M | — | — | -$50M | — | $26M |
| Sep '23 | — | -$70M | — | — | -$52M | — | $65M |
| Jun '23 | — | -$71M | — | — | -$53M | — | $46M |
| Mar '23 | — | -$75M | — | — | -$39M | — | $49M |
| Dec '22 | — | -$75M | — | — | -$57M | — | $93M |
| Sep '22 | — | -$84M | — | — | -$65M | — | $65M |
| Jun '22 | — | $18M | — | — | -$65M | — | $71M |
| Mar '22 | — | -$88M | — | — | -$87M | — | $102M |
| Dec '21 | — | -$93M | — | — | -$37M | — | $106M |
| Sep '21 | — | -$85M | — | — | -$63M | — | $113M |
| Jun '21 | — | -$84M | — | — | -$64M | — | $124M |
Valuation over time
How the market has priced ATRA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 5.0× (Dec '25) to 2.8× (Jun '26).
- The price-to-sales ratio has risen from 0.6× (Jan '24) to 0.8× (Jun '26).
P/E
P/S
Frequently asked questions
Is ATRA growing its revenue and profit?
Over the past 5 years, Atara Biotherapeutics, Inc.'s revenue has grown 275.3% per year. These are computed facts, not advice.
How much debt does ATRA have?
As of FY2025, Atara Biotherapeutics, Inc. reported — of total debt against $8M of cash; operating income covered interest expense 9.5×.
What is ATRA's profit margin?
In FY2025, gross margin was —, operating margin 29.7%, and net margin 27.1%.
What is ATRA's P/E ratio?
As of Jun '26, Atara Biotherapeutics, Inc. traded at a price-to-earnings ratio of about 2.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.